

# Gabriella Fontanini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8118049/publications.pdf>

Version: 2024-02-01

221  
papers

9,106  
citations

38742

50  
h-index

53230

85  
g-index

224  
all docs

224  
docs citations

224  
times ranked

10495  
citing authors

#	ARTICLE	IF	CITATIONS
1	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. <i>Lancet Oncology</i> , The, 2015, 16, 1306-1315.	10.7	835
2	ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. <i>Cancer Research</i> , 2002, 62, 7284-90.	0.9	463
3	Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. <i>Clinical Cancer Research</i> , 2003, 9, 1546-56.	7.0	263
4	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. <i>Lancet Oncology</i> , The, 2010, 11, 845-852.	10.7	234
5	A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. <i>Nature Genetics</i> , 2014, 46, 844-849.	21.4	208
6	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 497-507.	10.7	196
7	Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin remodelling genes as major players and a prognostic role for <i>TERT</i> , <i>RB1</i> , <i>MEN1</i> and <i>KMT2D</i> . <i>Journal of Pathology</i> , 2017, 241, 488-500.	4.5	179
8	Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. <i>Journal of Pathology</i> , 1995, 177, 57-63.	4.5	166
9	N-ras Mutation in Poorly Differentiated Thyroid Carcinomas: Correlation with Bone Metastases and Inverse Correlation to Thyroglobulin Expression. <i>Thyroid</i> , 2000, 10, 19-23.	4.5	159
10	Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. <i>Aids</i> , 1994, 8, 1237-1244.	2.2	147
11	Mechanical Prevention of Distal Embolization During Primary Angioplasty. <i>Circulation</i> , 2003, 108, 171-176.	1.6	147
12	Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7312-7319.	7.0	139
13	Advanced Stage Thymomas and Thymic Carcinomas: Results of Multimodality Treatments. <i>Annals of Thoracic Surgery</i> , 2005, 79, 1840-1844.	1.3	133
14	Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2015, 136, 83-90.	5.1	126
15	Small cell lung carcinoma (SCLC): the angiogenic phenomenon. <i>European Journal of Cardio-thoracic Surgery</i> , 2002, 21, 1105-1110.	1.4	124
16	Percutaneous radiofrequency ablation of lung tumours: results in the mid-term. <i>European Journal of Cardio-thoracic Surgery</i> , 2006, 30, 177-183.	1.4	121
17	Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1993, 106, 80-88.	0.8	111
18	Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A. <i>Journal of the National Cancer Institute</i> , 1996, 88, 1770-1776.	6.3	109

#	ARTICLE	IF	CITATIONS
19	Mutational Analysis in Cytological Specimens of Advanced Lung Adenocarcinoma: A Sensitive Method for Molecular Diagnosis. <i>Journal of Thoracic Oncology</i> , 2007, 2, 1086-1090.	1.1	102
20	Osteopontin Expression and Prognostic Significance in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 6459-6465.	7.0	98
21	Distal embolization during primary angioplasty: Histopathologic features and predictability. <i>American Heart Journal</i> , 2005, 150, 102-108.	2.7	97
22	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 988-994.	3.7	94
23	<i>ALK</i> Rearrangement in a Large Series of Consecutive Non-Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1449-1458.	2.5	93
24	Expression and Mutational Status of c-kit in Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 4101-4108.	7.0	87
25	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for <i>RAS</i> and <i>BRAF</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 529.	7.1	87
26	Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma. <i>Clinical Cancer Research</i> , 2005, 11, 5639-5644.	7.0	83
27	Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review. <i>Diagnostics</i> , 2020, 10, 521.	2.6	83
28	Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 876-887.	10.7	83
29	Angiogenesis: An indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. <i>Annals of Thoracic Surgery</i> , 1994, 57, 1534-1539.	1.3	81
30	The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer. <i>Cancer</i> , 1992, 70, 1520-1527.	4.1	78
31	microRNA classifiers are powerful diagnostic/prognostic tools in <i>ALK</i> , <i>EGFR</i> , and <i>KRAS</i> -driven lung cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14924-14929.	7.1	74
32	Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1651-1661.	1.1	73
33	Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E288-E296.	3.6	71
34	Class 1, 2, and 3 <i>BRAF</i> -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. <i>Clinical Cancer Research</i> , 2019, 25, 3954-3961.	7.0	67
35	Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 567-577.	2.8	64
36	TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12468-12473.	7.1	63

#	ARTICLE	IF	CITATIONS
37	Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (Stage IIIA-N2): Impact of adjuvant therapies in a subset of patients at high risk of recurrence. , 1996, 78, 409-415.		60
38	The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. Human Pathology, 1999, 30, 788-794.	2.0	59
39	Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. Journal of Cellular Physiology, 2006, 208, 344-353.	4.1	59
40	Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma. Modern Pathology, 2015, 28, 487-497.	5.5	59
41	Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 177-184.	2.8	59
42	WWOX Expression in Different Histologic Types and Subtypes of Non-Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 884-891.	7.0	58
43	Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathology, 2017, 125, 615-626.	2.4	58
44	Radiofrequency Ablation of Lung Malignancies: Where Do We Stand?. CardioVascular and Interventional Radiology, 2004, 27, 581-590.	2.0	56
45	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. British Journal of Cancer, 2016, 114, 30-36.	6.4	56
46	Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Scientific Reports, 2017, 7, 9388.	3.3	56
47	Most peripheral, node-negative, non-small-cell lung cancers have low proliferative rates and no intratumoral and peritumoral blood and lymphatic vessel invasion. Journal of Thoracic and Cardiovascular Surgery, 1992, 104, 892-899.	0.8	55
48	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. European Journal of Cancer, 2017, 73, 74-84.	2.8	54
49	Biologic effects of radiofrequency thermal ablation on non-small cell lung cancer: Results of a pilot study. Journal of Thoracic and Cardiovascular Surgery, 2006, 131, 1002-1006.	0.8	53
50	Let-7g and miR-21 expression in non-small cell lung cancer: Correlation with clinicopathological and molecular features. International Journal of Oncology, 2013, 43, 765-774.	3.3	53
51	Thermal Ablation of Lung Tissue: In Vivo Experimental Comparison of Microwave and Radiofrequency. CardioVascular and Interventional Radiology, 2010, 33, 818-827.	2.0	52
52	Human non-small cell lung cancer: P53 protein accumulation is an early event and persists during metastatic progression. Journal of Pathology, 1994, 174, 23-31.	4.5	51
53	Galectin-3 and Oncofetal-Fibronectin Expression in Thyroid Neoplasia as Assessed by Reverse Transcription-Polymerase Chain Reaction and Immunohistochemistry in Cytologic and Pathologic Specimens. Thyroid, 2003, 13, 765-770.	4.5	51
54	Cyclin D1 Overexpression in Thyroid Carcinomas: Relation with Clinico-Pathological Parameters, Retinoblastoma Gene Product, and Ki67 Labeling Index. Thyroid, 2000, 10, 741-746.	4.5	50

#	ARTICLE	IF	CITATIONS
55	CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E528-E536.	3.6	49
56	Sleeve and wedge parenchyma-sparing bronchial resections in low-grade neoplasms of the bronchial airway. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 134, 373-377.	0.8	47
57	Gene promoter methylation in colorectal cancer and healthy adjacent mucosa specimens. <i>Epigenetics</i> , 2014, 9, 621-633.	2.7	47
58	Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries. <i>Cancer Cytopathology</i> , 2020, 128, 885-894.	2.4	47
59	MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies. <i>Clinical Colorectal Cancer</i> , 2014, 13, 37-45.e4.	2.3	46
60	CLM3, a Multitarget Tyrosine Kinase Inhibitor With Antiangiogenic Properties, Is Active Against Primary Anaplastic Thyroid Cancer In Vitro and In Vivo. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E572-E581.	3.6	46
61	Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. <i>European Journal of Cancer</i> , 2005, 41, 2828-2835.	2.8	45
62	Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2011, 6, 395-396.	1.1	44
63	Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. <i>Aids</i> , 1996, 10, 701-710.	2.2	42
64	Intraoperative sentinel lymph node mapping in stage I non-small cell lung cancer: detection of micrometastases by polymerase chain reaction. <i>European Journal of Cardio-thoracic Surgery</i> , 2008, 34, 181-186.	1.4	41
65	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 4312-4322.	7.0	41
66	Different estrogen receptor $\beta$ expression in distinct histologic subtypes of lung adenocarcinoma. <i>Human Pathology</i> , 2008, 39, 1465-1473.	2.0	40
67	Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: Comparison with histological assessment. <i>Cancer Cytopathology</i> , 2014, 122, 445-453.	2.4	40
68	The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103436.	4.4	40
69	The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review. <i>Journal of Thoracic Disease</i> , 2018, 10, S276-S284.	1.4	39
70	Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. <i>Cancer Cytopathology</i> , 2019, 127, 285-296.	2.4	39
71	Cytokine Production by a New Undifferentiated Human Thyroid Carcinoma Cell Line, FB-11. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 4094-4100.	3.6	38
72	A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2007, 31, 529-534.	1.4	38

#	ARTICLE	IF	CITATIONS
73	Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months. <i>Experimental Hematology and Oncology</i> , 2017, 6, 6.	5.0	38
74	Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma. <i>Cancer Cell International</i> , 2017, 17, 105.	4.1	38
75	Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer. <i>European Journal of Cancer</i> , 1994, 30, 171-174.	2.8	37
76	Tryptase Mast Cells in Malignant Pleural Mesothelioma as an Independent Favorable Prognostic Factor. <i>Journal of Thoracic Oncology</i> , 2009, 4, 348-354.	1.1	37
77	Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1857-1866.e2.	0.8	37
78	Surgery for malignant pleural mesothelioma: an international guidelines review. <i>Journal of Thoracic Disease</i> , 2018, 10, S285-S292.	1.4	37
79	Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. <i>European Journal of Pharmacology</i> , 2009, 619, 8-14.	3.5	35
80	Overexpression of the cohesin-core subunit SMC1A contributes to colorectal cancer development. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 108.	8.6	34
81	Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1465-E1473.	3.6	33
82	Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology?. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 480-489.	2.5	33
83	Neovascularization: A putative marker of malignancy in non-small-cell-lung-cancer (NSCLC) development. <i>Journal of Thoracic Oncology</i> , 1996, 67, 615-619.		32
84	Interleukin-8 in non-small cell lung carcinoma: Relation with angiogenic pattern and p53 alterations. <i>Lung Cancer</i> , 2005, 50, 309-317.	2.0	31
85	<i>BRAF</i> Status of Follicular Variant of Papillary Thyroid Carcinoma and its Relationship to Its Clinical and Cytological Features. <i>Thyroid</i> , 2010, 20, 1263-1270.	4.5	31
86	Irinotecan Synergistically Enhances the Antiproliferative and Proapoptotic Effects of Axitinib In Vitro and Improves Its Anticancer Activity In Vivo. <i>Neoplasia</i> , 2011, 13, 217-IN3.	5.3	31
87	Malignancies Within Rhinophyma: Report of Three New Cases and Review of the Literature. <i>Aesthetic Plastic Surgery</i> , 2012, 36, 396-405.	0.9	31
88	Four-Modality Therapy in Malignant Pleural Mesothelioma: A Phase II Study. <i>Journal of Thoracic Oncology</i> , 2007, 2, 237-242.	1.1	30
89	Mutant cohesin drives chromosomal instability in early colorectal adenomas. <i>Human Molecular Genetics</i> , 2014, 23, 6773-6778.	2.9	30
90	Nodal upstaging evaluation in NSCLC patients treated by robotic lobectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 153-158.	2.4	30

#	ARTICLE	IF	CITATIONS
91	Prognostic significance of <i>K-Ras</i> mutation rate in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2015, 6, 31604-31612.	1.8	30
92	Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 809-816.	1.5	29
93	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. <i>European Journal of Cancer</i> , 2021, 146, 74-83.	2.8	29
94	MERRF syndrome without ragged-red fibers: The need for molecular diagnosis. <i>Biochemical and Biophysical Research Communications</i> , 2007, 354, 1058-1060.	2.1	28
95	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. <i>Targeted Oncology</i> , 2014, 9, 205-214.	3.6	27
96	Suppression of Fas Expression and Down-Regulation of Fas Ligand in Highly Aggressive Human Thyroid Carcinoma. <i>Laboratory Investigation</i> , 2000, 80, 1413-1419.	3.7	26
97	Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis. <i>Oncotarget</i> , 2017, 8, 2758-2770.	1.8	26
98	Response of normal and oncogene-transformed human mammary epithelial cells to transforming growth factor $\beta$ 1 (TGF- $\beta$ 1): Lack of growth-inhibitory effect on cells expressing the simian virus 40 large-t antigen. <i>International Journal of Cancer</i> , 1994, 56, 736-742.	5.1	25
99	Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: A population-based prospective study. <i>Oncology Reports</i> , 2009, 22, 683-91.	2.6	25
100	Differential Expression of Extracellular Matrix Constituents and Cell Adhesion Molecules between Malignant Pleural Mesothelioma and Mesothelial Hyperplasia. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1389-1395.	1.1	25
101	Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer. <i>Cancer Letters</i> , 2017, 411, 35-43.	7.2	25
102	Hippo pathway affects survival of cancer patients: extensive analysis of TCGA data and review of literature. <i>Scientific Reports</i> , 2018, 8, 10623.	3.3	25
103	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019, 109, 175-182.	2.8	25
104	Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. <i>European Journal of Cancer</i> , 2019, 110, 32-41.	2.8	25
105	CXC Chemokine Receptor 4 Immunodetection in the Follicular Variant of Papillary Thyroid Carcinoma: Comparison to Galectin-3 and Hector Battifora Mesothelial Cell-1. <i>Thyroid</i> , 2010, 20, 495-504.	4.5	24
106	P2X7 mRNA expression in non-small cell lung cancer: MicroRNA regulation and prognostic value. <i>Oncology Letters</i> , 2015, 9, 449-453.	1.8	24
107	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. <i>Journal of Clinical Oncology</i> , 2022, 40, 2878-2888.	1.6	24
108	Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 787-792.	1.8	23



#	ARTICLE	IF	CITATIONS
109	Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review. <i>Journal of Thoracic Disease</i> , 2018, 10, S342-S352.	1.4	23
110	Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer. <i>Oncogene</i> , 2001, 20, 6632-6637.	5.9	22
111	Digital Slides as an Effective Tool for Programmed Death Ligand 1 Combined Positive Score Assessment and Training: Lessons Learned from the "Programmed Death Ligand 1 Key Learning Program in Head-and-Neck Squamous Cell Carcinoma". <i>Journal of Pathology Informatics</i> , 2021, 12, 1.	1.7	22
112	TP53 expression levels in relation to haplotypes of the TP53 internal promoter region. <i>Human Mutation</i> , 2010, 31, 456-465.	2.5	21
113	CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo. <i>Molecular and Cellular Endocrinology</i> , 2014, 393, 56-64.	3.2	21
114	Lung metastasectomy after colorectal cancer: prognostic impact of resection margin on long term survival, a retrospective cohort study. <i>International Journal of Colorectal Disease</i> , 2020, 35, 9-18.	2.2	21
115	Effect of the p53 Codon 72 and Intron 3 Polymorphisms on Non-Small Cell Lung Cancer (NSCLC) Prognosis. <i>Cancer Investigation</i> , 2008, 26, 168-172.	1.3	20
116	Phosphatidylinositol-3-kinase $\beta$ catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours. <i>Oncology Reports</i> , 2012, 28, 1559-1566.	2.6	19
117	p95HER2 Truncated Form in Resected Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 520-527.	1.1	19
118	Glomus tumor of the shoulder: A case report and review of the literature. <i>Oncology Letters</i> , 2013, 6, 1021-1024.	1.8	19
119	CD34 Microvessel Density and VEGF Expression in Basal and Squamous Cell Carcinoma. <i>Pathology Research and Practice</i> , 2003, 199, 705-712.	2.3	18
120	Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines. <i>Genes and Cancer</i> , 2017, 8, 438-452.	1.9	18
121	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018, 118, 955-965.	6.4	17
122	Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe. <i>Journal of Clinical Pathology</i> , 2021, 74, 391-395.	2.0	17
123	Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report. <i>Oncology Letters</i> , 2017, 14, 5947-5951.	1.8	16
124	EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas. <i>Cancer Biomarkers</i> , 2018, 21, 731-741.	1.7	16
125	Screen-detected multiple primary lung cancers in the ITALUNG trial. <i>Journal of Thoracic Disease</i> , 2018, 10, 1058-1066.	1.4	16
126	P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC). <i>Journal of Negative Results in BioMedicine</i> , 2014, 13, 16.	1.4	15



#	ARTICLE	IF	CITATIONS
127	EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. <i>Oncology Reports</i> , 2016, 36, 1166-1172.	2.6	15
128	Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma. <i>Oncology Letters</i> , 2016, 12, 4009-4012.	1.8	15
129	COVID-19 pandemic impact on cytopathology practice in the post-lockdown period: An international, multicenter study. <i>Cancer Cytopathology</i> , 2022, 130, 344-351.	2.4	15
130	Expression of endothelin 1 and its angiogenic role in meningiomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 449, 546-553.	2.8	14
131	The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences. <i>Journal of Translational Medicine</i> , 2015, 13, 287.	4.4	14
132	Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. <i>Biochemical Pharmacology</i> , 2019, 164, 94-105.	4.4	14
133	Laryngotracheal resection for a post-tracheotomy stenosis in a patient with coronavirus disease 2019 (COVID-19). <i>JTCVS Techniques</i> , 2020, 4, 360-364.	0.4	14
134	Potential of the malignant phenotype of the undifferentiated ARO thyroid cell line by insertion of the <i>bcl-2</i> gene. , 1999, 81, 956-962.		13
135	An "inflammatory" mitochondrial myopathy. A case report. <i>Neuromuscular Disorders</i> , 2013, 23, 907-910.	0.6	13
136	EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 77.	8.6	13
137	N2 lung cancer is not all the same: an analysis of different prognostic groups. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2018, 27, 720-726.	1.1	13
138	Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network. <i>Pathologica</i> , 2021, 113, 262-271.	3.4	13
139	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 155, 73-84.	2.8	13
140	Detection of <i>Mycobacterium tuberculosis</i> from paraffin-embedded tissues by GeneXpert MTB/RIF. <i>Tuberculosis</i> , 2017, 106, 53-55.	1.9	12
141	Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer. <i>Pharmacological Research</i> , 2020, 158, 104920.	7.1	12
142	Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record. <i>Cancers</i> , 2020, 12, 1800.	3.7	12
143	Applications of tissue microarray technology in immunohistochemistry: A study on c-kit expression in small cell lung cancer. <i>Human Pathology</i> , 2004, 35, 1347-1352.	2.0	11
144	Expression of Cyclooxygenase-2 and Its Correlation with Vasogenic Brain Edema in Human Intracranial Meningiomas. <i>Cancer Investigation</i> , 2007, 25, 555-562.	1.3	11

#	ARTICLE	IF	CITATIONS
145	CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma. <i>Human Pathology</i> , 2007, 38, 1563-1568.	2.0	11
146	Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas. <i>Scientific Reports</i> , 2019, 9, 3536.	3.3	11
147	Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. <i>British Journal of Cancer</i> , 2019, 120, 522-526.	6.4	11
148	Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 685-698.	2.8	11
149	Mutations of Fas (APO-1/CD95) and p53 Genes in Nonmelanoma Skin Cancer. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 112-118.	1.2	10
150	The Role of Somatostatin in Vasogenic Meningioma Associated Brain Edema. <i>Tumori</i> , 2003, 89, 136-140.	1.1	10
151	EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: A case report. <i>Lung Cancer</i> , 2013, 81, 297-301.	2.0	10
152	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 874.	2.6	10
153	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , 2020, 135, 78-88.	2.8	10
154	Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study. <i>Diagnostics</i> , 2022, 12, 477.	2.6	10
155	The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1407-1412.	2.3	9
156	Reference standards for gene fusion molecular assays on cytological samples: an international validation study. <i>Journal of Clinical Pathology</i> , 2023, 76, 47-52.	2.0	9
157	Prevalence of Delta-Like Protein 3 in a Consecutive Series of Surgically Resected Lung Neuroendocrine Neoplasms. <i>Frontiers in Oncology</i> , 2021, 11, 729765.	2.8	9
158	Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3519-3519.	1.6	9
159	Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3543-3543.	1.6	9
160	The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features. <i>Cancer Treatment Reviews</i> , 2022, 106, 102382.	7.7	9
161	Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything? <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2010, 10, 572-576.	1.1	8
162	KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung. <i>Lung Cancer</i> , 2013, 81, 377-381.	2.0	8

#	ARTICLE	IF	CITATIONS
163	Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1783-1793.	2.5	8
164	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): Updated survival results and final molecular subgroups analyses.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3510-3510.	1.6	8
165	Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009, 1, 167-181.	3.2	7
166	Discordant somatic and germline <i>VEGF-A</i> genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. <i>Pharmacogenomics</i> , 2009, 10, 1225-1229.	1.3	7
167	KRAS and BRAF genotyping of synchronous colorectal carcinomas. <i>Oncology Letters</i> , 2014, 7, 1532-1536.	1.8	7
168	Management of Italian Patients With Advanced Non-Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study. <i>Clinical Lung Cancer</i> , 2014, 15, 338-345.e1.	2.6	7
169	Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report. <i>Oncology Letters</i> , 2015, 9, 1537-1540.	1.8	7
170	Differential Diagnosis of Malignant Pleural Mesothelioma on Cytology. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 457-466.	2.8	7
171	Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms. <i>Cancers</i> , 2021, 13, 4875.	3.7	7
172	Regulation of telomerase and its hTERT messenger in colorectal cancer. <i>Oncology Reports</i> , 0, , .	2.6	7
173	Novel <i>MTCYB</i> mutation in a young patient with recurrent stroke-like episodes and status epilepticus. <i>American Journal of Medical Genetics, Part A</i> , 2014, 164, 2922-2925.	1.2	6
174	Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 3828.	3.7	6
175	TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study. <i>Journal of Clinical Pathology</i> , 2022, 75, 416-421.	2.0	6
176	Consensus molecular subtypes and CRC assigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4016-4016.	1.6	6
177	Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma. <i>Journal of Chemotherapy</i> , 2021, 33, 198-202.	1.5	5
178	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 153, 16-26.	2.8	5
179	Morphology and Progression of Preneoplastic Changes in Methylcholanthrene-Induced Mouse Mammary Tumorigenesis. <i>Tumori</i> , 1985, 71, 1-11.	1.1	4
180	Receptor Status, Proliferating Activity, and c-erbB2 Oncoprotein.. <i>Annals of the New York Academy of Sciences</i> , 1993, 698, 167-173.	3.8	4

#	ARTICLE	IF	CITATIONS
181	Mutations of Fas (APO-1/CD95) and p53 Genes in Nonmelanoma Skin Cancer. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 112-118.	1.2	4
182	Immunohistochemical and Molecular Study of Radiation-Induced Multiple Meningiomas with Pleural and Pulmonary Metastasis. <i>Tumori</i> , 2004, 90, 328-332.	1.1	4
183	Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 887-900.	2.4	4
184	Feasibility of BRCA1/2 Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series. <i>Diagnostics</i> , 2021, 11, 1046.	2.6	4
185	Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3596-3596.	1.6	4
186	Laser capture microdissection: A tool for the molecular characterization of histologic subtypes of lung adenocarcinoma. <i>International Journal of Molecular Medicine</i> , 2009, 24, 473-9.	4.0	3
187	Prognostic role of TPL2 in early-stage non-small cell lung cancer. <i>Molecular Medicine Reports</i> , 2017, 15, 3451-3458.	2.4	3
188	Novel prognostic markers for epithelioid malignant pleural mesothelioma.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20028-e20028.	1.6	3
189	A gene expression-based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations. <i>Oncology Letters</i> , 2020, 19, 1060-1065.	1.8	3
190	Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients. <i>Oncology Reports</i> , 0, , .	2.6	2
191	KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3091-3096.	3.6	2
192	Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. <i>Biomedical Reports</i> , 2018, 9, 198-205.	2.0	2
193	Distinct Angiogenic microRNA-mRNA Expression Profiles Among Subtypes of Lung Adenocarcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 1089-1096.	1.9	2
194	Crizotinib in ROS1 and MET Deregulated NSCLC Response. <i>Clinical Cancer Research</i> , 2020, 26, 1775-1775.	7.0	2
195	Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation. <i>Frontiers in Oncology</i> , 2021, 11, 674604.	2.8	2
196	Conventional Transbronchial Needle Aspiration (cTBNA) and EBUS-Guided Transbronchial Needle Aspiration (EBUS-TBNA): A Retrospective Study on the Comparison of the Two Methods for Diagnostic Adequacy in Molecular Analysis. <i>Journal of Molecular Pathology</i> , 2021, 2, 296-305.	1.2	2
197	Expression of miRNA-25 in young and old lung adenocarcinoma. <i>Journal of Research in Medical Sciences</i> , 2021, 26, 132.	0.9	2
198	Gene Expression Analysis of Biphasic Pleural Mesothelioma: New Potential Diagnostic and Prognostic Markers. <i>Diagnostics</i> , 2022, 12, 674.	2.6	2

#	ARTICLE	IF	CITATIONS
199	Inflammatory Profiles of Tracheal Biopsies From SARS-CoV-2 Patients. <i>Frontiers in Microbiology</i> , 2022, 13, 851460.	3.5	2
200	Distal embolization during angioplasty for acute myocardial infarction: is pharmacological protection enough?. <i>Thrombosis and Haemostasis</i> , 2005, 94, 680-681.	3.4	1
201	Aberrant expression of anaplastic lymphoma kinase in lung adenocarcinoma: Analysis of circulating free tumor RNA using one-step reverse transcription-polymerase chain reaction. <i>Molecular Medicine Reports</i> , 2016, 14, 2238-2242.	2.4	1
202	Potential of the malignant phenotype of the undifferentiated ARO thyroid cell line by insertion of the bcl2 gene. <i>International Journal of Cancer</i> , 1999, 81, 956-962.	5.1	1
203	Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11508-11508.	1.6	1
204	MET exon 14 mutations in advanced lung adenocarcinoma: Frequency and coexisting alterations.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20656-e20656.	1.6	1
205	Tumor mutational load, microsatellite instability and actionable mutations in metastatic colorectal cancer: Results from the TRIBE2 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4077-4077.	1.6	1
206	Factors that Affect Metastasis in Virus-Induced Mouse Mammary Tumors. <i>Tumori</i> , 1984, 70, 131-136.	1.1	0
207	Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation. <i>Molecular Medicine Reports</i> , 0, , .	2.4	0
208	Advances in molecular diagnostics for mitochondrial diseases. <i>Expert Opinion on Medical Diagnostics</i> , 2009, 3, 557-569.	1.6	0
209	Recurrent Spontaneous Pneumothorax Hiding a Rare Pulmonary Tumor in a 4-Year-Old Girl. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1847.	1.3	0
210	Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study. <i>Annals of Oncology</i> , 2017, 28, iii94-iii95.	1.2	0
211	In Reply. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1452-1452.	2.5	0
212	In Reply. <i>Oncologist</i> , 2021, 26, e1895-e1896.	3.7	0
213	BRAF and KRAS mutations in liver-resected metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, 476-476.	1.6	0
214	Abstract 3265: Homeobox B9 (HOXB9) sustains anti-VEGF treatment resistance in gastrointestinal tumors. , 2016, , .		0
215	Abstract LB-238: Dissecting primary resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) inRASandBRAFWild-type (wt) metastatic colorectal cancer (mCRC). , 2017, , .		0
216	Histopathologic response and growth patterns of colorectal cancer liver metastases (CRCLM) in patients treated with triplets plus bevacizumab (bev) or anti-EGFRs.. <i>Journal of Clinical Oncology</i> , 2018, 36, 636-636.	1.6	0

#	ARTICLE	IF	CITATIONS
217	The immune-profile of mismatch repair deficient (dMMR) colorectal cancers (CRCs) differs according to primary tumor sidedness.. Journal of Clinical Oncology, 2018, 36, e15593-e15593.	1.6	0
218	Abstract 1823: Identification of molecular determinants of vinorelbine resistance in BRAF(V600E) mutated chemorefractory metastatic colorectal cancer patients. , 2018, , .		0
219	Pathological Diagnosis of Mesothelioma. , 2019, , 99-122.		0
220	Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer. American Journal of Cancer Research, 2020, 10, 2120-2127.	1.4	0
221	Angiogenesis and Cancer. Surgical Technology International, 2000, IX, 25-32.	0.2	0